AlloVir, Inc.

Equities

ALVR

US0198181036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 12/06/2024 am IST			5-day change	1st Jan Change
0.7957 ^USD	+8.21%		+4.07%	+17.05%

11/06	AlloVir, Inc. Enter into Termination of Sublease Agreement with AMAG Pharmaceuticals, Inc	CI
13/05	AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

AlloVir, Inc. Announces Departure of Chief Medical Officer Augustin Melian

December 17, 2021 at 02:35 am IST

AlloVir, Inc. announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year. Although officially leaving the company, Dr. Melian has agreed to work with AlloVir in an advisory capacity to ensure a smooth transition.

Latest news about AlloVir, Inc.

AlloVir, Inc. Enter into Termination of Sublease Agreement with AMAG Pharmaceuticals, Inc	12/06	CI
AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
North American Morning Briefing : Markets on Hold -2-	20/03	DJ
AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
North American Morning Briefing : Stock Futures -2-	13/03	DJ
North American Morning Briefing : Stock Futures -2-	21/02	DJ
North American Morning Briefing : S&P 500 Hovers Near Record as Interest Rate Optimism Holds Sway	27/12	DJ
Sector Update: Health Care	23/12	MT
Morgan Stanley Downgrades AlloVir to Equalweight From Overweight, Cuts Price Target to $1 From $20	23/12	MT
AlloVir Shares Plummet as Global Trials of Anti-Viral T-Cell Therapy to be Discontinued	23/12	MT
Top Midday Decliners	23/12	MT
Sector Update: Health Care Stocks Gain in Late Afternoon	23/12	MT
AlloVir to Review Strategic Alternatives for the Company and Its Portfolio of Virus-Specific T Cell Therapies	22/12	CI
AlloVir scraps late-stage studies testing lead cell therapy	22/12	RE
AlloVir scraps late-stage studies testing antiviral cell therapy	22/12	RE
AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy	22/12	CI
Leerink Partners Downgrades AlloVir to Market Perform From Outperform, Cuts Price Target to $1 From $14	22/12	MT
Piper Sandler Downgrades AlloVir to Neutral From Overweight, Cuts Price Target to $1.50 From $27	22/12	MT
JPMorgan Downgrades AlloVir to Underweight From Overweight	22/12	MT
AlloVir, Inc.(NasdaqGS:ALVR) dropped from NASDAQ Biotechnology Index	15/12	CI
AlloVir, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11	CI
Certain Restricted Stock Units of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	20/23/20	CI
Certain Stock Options of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	20/23/20	CI
Certain Common Stock of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	20/23/20	CI
Transcript : AlloVir, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 04:55 PM	12/23/12

Chart AlloVir, Inc.

Duration

Period

More charts

Company Profile

AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyâs proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.7957 USD

Average target price

0.975 USD

Spread / Average Target

+22.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALLOVIR, INC.	+17.05%	90.26M
VERTEX PHARMACEUTICALS INCORPORATED	+18.34%	124B
REGENERON PHARMACEUTICALS, INC.	+15.06%	109B
BIONTECH SE	-6.39%	23.84B
ARGENX SE	+0.96%	22.42B
GENMAB A/S	-15.27%	17.5B
WUXI APPTEC CO., LTD.	-41.64%	16.43B
BEIGENE, LTD.	-12.07%	16.61B
NEUROCRINE BIOSCIENCES, INC.	+1.05%	13.4B
SAREPTA THERAPEUTICS, INC.	+25.87%	11.47B

Bio Therapeutic Drugs